Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
NCI-MATCH closed this year, as three new precision medicine trials — ComboMATCH, MyeloMATCH and iMATCH — are getting underway.
The test shows which patients with clonal hematopoiesis, a precancerous state, are more likely to develop blood cancers.
Despite being the only current cure for MDS, transplants generally haven’t been offered to older patients.
The drug targets cancer’s survival proteins, making them more vulnerable to treatments that cause cancer cells to self-destruct.
Some patients develop a secondary blood cancer after receiving radiation or chemotherapy treatment for their initial cancer diagnosis
The trial will test the drug acalabrutinib in those with acute myeloid leukemia, acute lymphoblastic leukemia and myelodysplastic syndromes.
Here are latest arrivals approved by the Food and Drug Administration.
This represents an important advance for patients who previously needed to visit a health care facility.
Researchers believe their greater understanding of leukemia stem cells will lead to more treatment options for people with the blood cancer.
ASH 2018 conference highlights precision medicine, machine learning and gut microbiome.
NK cells are “first responders” that rapidly detect and attack virus-infected cells and tumor cells, and can also help prevent metastasis.
The study used two FDA-approved drugs to the pre-leukemic cells while leaving healthy stem cells alone.
Trials for head and neck cancer, pancreatic cancer, acute myeloid leukemia and myelodysplastic syndrome, among others, will receive funding.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.